Unknown

Dataset Information

B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies.


ABSTRACT: Outcomes of patients with multiple myeloma (MM) who become refractory to standard therapies are particularly poor and novel agents are greatly needed to improve outcomes in such patients. B-cell maturation antigen (BCMA) has become an important therapeutic target in MM with three modalities of treatment in development including antibody-drug conjugates (ADCs), bispecific T-cell engagers (BITEs), and chimeric antigen receptor (CAR) T-cell therapies. Early clinical trials of anti-BCMA immunotherapeutics have demonstrated extremely promising results in heavily pretreated patients with relapsed/refractory MM (RRMM). Recently, belantamab mafodotin was the first anti-BCMA therapy to obtain approval in relapsed/refractory MM. This review summarizes the most updated efficacy and safety data from c

SUBMITTER: Sanchez L 

PROVIDER: S-EPMC7970693 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature